Blogs about NABI - Stockpickr! Your Source for Stock Ideas

Blogs about NABI

Blogs	Description	Date Updated
Chapman: "Nabi is not yet worthy of our disdain or disgust"	In a 13D filing Friday afternoon on Nabi Biopharmaceuticals (Nasdaq: NABI), Chapman Capital disclosed a 6.6% stake in the company and issued a press release announcing its support for the maximization of Nabi shareholder value via a three-step transaction: 1) FDA approval of Nabi’s BLA for Nabi-HB Intravenous; 2) the distribution of the proceeds from the sale of Nabi Biologics; and 3) partnering/licensing of Nabi’s vaccine pipeline led by smoking cessation drug, NicVAX (Nicotine Conjugate Va...	June 18, 2007
Loeb's Third Point Raises Stake in Nabi Biopharmaceuticals (NABI) to 11.4%	In an amended 13D filing this afternoon on Nabi Biopharmaceuticals (Nasdaq: NABI), Dan Loeb's Third Point LLC disclosed they raised their stake to 11.4% from 9.5%, buying 1.14 million shares from 05/08-05/10.Third Point has representatives on the board of directors of Nabi as part of a 2006 settlement.You can get 13D reports and others e-mailed to you in real-time by signing up for StreetInsider.com Premium...	May 11, 2007
Pre-Market Stock News (May 3, 2007)	(AIZ) Assurant $1.42 EPS vs $1.20e.(AMD) Adanced Micro Devices holds a shareholder meeting today.(APKT) Acme Packet $0.08 EPS vs $0.07e.(BARE) Bare Escentuals $0.22 EPS vs $0.19e.(CAI) CACI International $0.59 EPS vs $0.59e.(CBS) CBS $0.33 EPS vs $0.32e.(CCUR) Concur Tech $0.12 EPS vs $0.07e.(CEGE) Cell Genesys released tentative Phase I Alzheimer’s results for its #110 molecule as safe and positive.(CELG) Celgene $0.20 EPS vs $0.21e; Fiscal Guidance $1.00 vs $1.04e; stock down 5%.(CGV) CGG Ve...	May 03, 2007
Wednesday's Top Biotech & Medical Stocks	by H.S. AyoubBioHealth Investor.comBiotechnologyINTL STEM CELL CORP [ISCO.OB] +18.11% OBAGI MEDICAL [OMPI] +13.83% NABI BIOPHARMACEUT [NABI] +11.28% ZIOPHARM ONCOLOGY IN [ZIOP] +11.11% HESKA CORPORATION [HSKA] +10.80% Diagnostic Substances NYMOX PHARM CORP [NYMX] +8.13% IMMUCOR INC [BLUD] +5.96% GENE LOGIC INC [GLGC] +5.26% INTERLEUKIN GENETICS [ILI] +4.89% SYNTA PHARMACEUTICAL [SNTA] Drug Delivery EMISPHERE TECH [EMIS] +5.54% NOVADEL PHARMA INC [NVD] +4.75% SKYEPHARMA PLC [SKYE] +4.09...	May 03, 2007
StreetInsider.com After-Hours Movers 04/19	Mentor Corporation (NYSE: MNT) 17% LOWER; expects Fiscal 2007 sales of $300 million to $302 million. The Company had previously guided that sales would be in the range of $305 million to $315 million. The consensus is $309.3 million. Mentor sees 2008 sales of $340 million to $355 million. The consensus is $371.9 million.Robert Half (NYSE: RHI) 11% LOWER; reports Q1 EPS of $0.42, 4 cents worse than estimates.(0.46) Revenues were $1.1 billion vs. $1.10 billion consensus.Stamps.com (Nasdaq: STMP) 8...	April 20, 2007
Lightning Round	BullishBrocade (BRCD), Halliburton (HAL), Transocean (RIG), GlobalSantaFe (GSF), Henry Schein (HSIC), Akamai (AKAM), Gerdau (GGB), Cheesecake Factory (CAKE), Diageo (DEO), Gilead Sciences (GILD), Genzyme (GENZ), Celegene (CELG), Allegan (AGN) and Global Sources (GSOL).BearishHelmerich & Payne (HP), Constellation Brands (STZ), LCA-Vision (LCAV), Sonoco (SON) and Bemis (BMS).Sudden DeathBullishCelegene (CELG), Alcoa (AA) and Abbott Labs.BearishNabi Biopharmaceuticals (NABI) and Wyeth (WYE)....	April 02, 2007
Cramer Pick: Activist Investors & Underperforming Management	Cramer also has a pick of underperforming management and activist activity. This pick is PDL BioPharma (PDLI-NASDAQ). The company gets royalties from Avastin and Herceptin from Genentech, but the company has made many bad decisions. PDLI now has an activist investor called Third Point LLC that wanst a board seat. This group is experienced, and now they think the stock should be worth $39 to $59 instead of the $20+ area now. They have invested in NABI and LGND as pas...	March 26, 2007
StreetInsider.com After-hours Movers 03/02	StreetInsider.com After-hours Movers: American Oriental (NYSE: AOB) 20% LOWER; reports Q4 EPS of $0.17 versus the consensus of $0.16. Revenues came in at $41.3 million versus the consensus of $37.46 million. Sees Q1 EPS of $0.10 versus the consensus of $0.10. Sees Q1 revenues of $24-$25 million. Sees FY revenues of $143-$147 million versus the consensus of $144.7 million. Jo-Ann Stores Inc. (NYSE: JAS) 9% HIGHER; reports Q4 EPS of $1.05, versus the consensus of $0.98. Revenues came in ...	March 12, 2007

Enter search text here: